@article{3211273, title = "MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival.", author = "Nakopoulou, L. and Gakiopoulou, H. and Zervas, A. and Giannopoulou, I. and Constantinides, C. and Lazaris, A. C. and Liapis, H. and Kyriakou, G. and Dimopoulos, C.", journal = "Applied immunohistochemistry & molecular morphology : AIMM", year = "2001", volume = "9", number = "2", pages = "130--137", doi = "10.1097/00129039-200106000-00005", keywords = "Humans, Female, Male, Survival Rate, Aged, Adult, Middle Aged, Aged, 80 and over, Neoplasm Invasiveness, Immunohistochemistry, Disease-Free Survival, Proportional Hazards Models, In Situ Hybridization, Carcinoma, Transitional Cell/*enzymology/metabolism/mortality/pathology, Matrix Metalloproteinase 1/genetics/*metabolism, Matrix Metalloproteinase 3/*metabolism, Stromal Cells/enzymology/metabolism, Urinary Bladder Neoplasms/*enzymology/metabolism/mortality/pathology, Urinary Bladder/enzymology/metabolism/pathology", abstract = "Matrix metalloproteinases (MMPs) are proteolytic enzymes important at several points during multistep neoplastic progression. Although MMP-1 and MMP-3 have been implicated in the progression of various human cancers, their expression in bladder cancer has not been addressed. Immunohistochemistry (Strept-ABC-HRP method) and in situ hybridization were performed to detect MMP-1 protein, MMP-3 protein, and MMP-3 mRNA, respectively, in 59 transitional cell bladder carcinomas. To assess the role of these MMPs in bladder cancer, their expression was evaluated in relation to known clinicopathologic parameters and patients’ disease-free and overall survival. Immunoreactivity for MMP-1 and MMP-3 proteins was observed in the cytoplasm of cancer cells in 30.5% and 24% of samples, respectively. Transcripts for MMP-3 mRNA were localized in stromal cells in 71.2% of cases and in cancer cells in 49% of cases. MMP-1 immunoreactivity demonstrated a statistically significant association with deeply invasive and grade III tumors versus superficial and lower grade tumors. MMP-3 protein immunoreactivity and MMP-3 mRNA immunolocalization did not associate with the parameters studied. However, MMP-3 mRNA localization in stromal cells demonstrated a borderline association with poor patients’ disease-free and overall survival. In conclusion, the authors’ results demonstrate a differential expression between MMP-1 and MMP-3 in bladder cancer; MMP-1 appears to participate in invasiveness and possibly in loss of differentiation in urothelial carcinomas in contrast to MMP-3." }